TLDR: Professor Hong Jin-tae of Chungbuk National University has been awarded the 56th Korea-German Academic Award for his significant contributions to developing treatments for cancer and inflammatory neurological diseases. His research, which includes leveraging big data and artificial intelligence for new drug development, has earned him recognition as a top researcher in Korea.
Professor Hong Jin-tae from Chungbuk National University has been named the distinguished recipient of the 56th Korea-German Academic Awards. The announcement was made on October 22, 2025, by Handok, in conjunction with the Korean Pharmaceutical Association, highlighting Professor Hong’s profound impact on the pharmaceutical field.
The prestigious award recognizes Professor Hong’s extensive research and development efforts in creating treatments for various ailments, particularly cancer and inflammatory neurological diseases. His work has focused on understanding the molecular mechanisms and developing therapeutic strategies related to ‘CHI3L1’, a key factor in these conditions.
With a career spanning over 15 years, Professor Hong has demonstrated exceptional dedication to advancing Korean pharmaceuticals. He has twice served as the head of the Center for Advanced Research in Basic Medicine (MRC), where he spearheaded network research initiatives on cancer and other diseases. A notable aspect of his recent work includes pioneering new drug development strategies that integrate big data and artificial intelligence, showcasing a forward-thinking approach to medical innovation.
His academic prowess is evident in his prolific publication record, with over 200 papers published in esteemed international journals such as ‘Molecular Cancer’. These contributions have solidified his reputation as a leading researcher in Korea, reflected by an impressive average influence index (IF) of 6.4 and a citation index (D-index) of 80.
The Korea-German Academic Awards, established in 1970 by the Korean-German and Korean Pharmaceutical Association, aim to foster research excellence in the pharmaceutical sector. Recipients are selected based on their outstanding research achievements over more than 15 years and their active commitment to the development of Korean pharmaceuticals.
Also Read:
- BostonGene Secures Five 2025 Stevie® Awards for Pioneering AI in Oncology Technology
- South Korea’s Medical Korea 2025 Highlights AI’s Transformative Role in Healthcare and Global Collaboration
The award ceremony is scheduled to take place on October 23, 2025, at the Korean Pharmaceutical Association Autumn Conference, held at LeWest Hall A in the COEX Magok Convention Center. Professor Hong will be honored with a weak performance award and a prize of 20 million won.
